Co-infections are frequent in HIV patients; some of them may be AIDS-defining, while others share the same underlying virus mechanism [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222884 | PMC |
| http://dx.doi.org/10.3390/v15051097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Application of the COM-B model to facilitators and barriers to HIV and STI testing among people from Black African and Black Caribbean communities in the UK: a scoping review.
Sex Transm Infect
December 2024
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
Objective: Individuals from Black African and Black Caribbean communities (black communities) in the UK bear a disproportionate burden of HIV and sexually transmitted infections (STIs), while exhibiting lower testing rates. The aim of the scoping review was to summarise interventions developed to increase HIV/STI testing among black communities in the UK and describe the facilitators and barriers that influence testing uptake in these populations, according to the Capability Opportunity Motivation Behaviour (COM-B) approach.
Methods: Six databases were systematically searched to identify quantitative, qualitative and mixed-method studies evaluating the effectiveness of HIV/STI testing interventions among black communities in the UK, published from 2000 onwards.
Prevalence of HIV, HBV, and HCV infections and high-risk behaviors among women referred to drop-in centers in Lorestan Province, western Iran.
Arch Razi Inst
June 2024
Hepatitis Research Center, Department of Virology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) are known as the most common blood-borne viral infections worldwide. Individuals referring to drop-in centers (DICs) are considered high-risk people exposed to infection with blood-borne viruses. The purpose of this study was to investigate the prevalence of HIV, HBV, and HCV infections among women referred to DICs in Lorestan Province, western Iran.
View Article and Find Full Text PDFExtensive cervical lesion and treatment outcomes in women with HIV/HPV co-infection.
AIDS Res Ther
December 2024
Jennifer Tiu, ACTG Network Coordinating Center, Bethesda, USA.
Background: Cervical cancer is a common cancer worldwide, with > 85% of deaths occurring in Lower- and Middle-Income Countries where resources for screening programs are limited. Women living with HIV (WLHIV) are at increased risk. HPV test-and-treat is a screening strategy where women with HPV are offered ablative treatment of the cervix to reduce the risk of invasive cancer.
View Article and Find Full Text PDFReal-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients.
J Virus Erad
December 2024
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China.
Background: Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C (CHC) in China, especially those with HCV GT3b, cirrhosis, hepato-cellular carcinoma (HCC), or HCV/hepatitis B (HBV), HCV/HIV, or HCV/HBV/HIV coinfection.
Methods: In this real-world prospective observational study, we recruited patients from the West China Hospital and Public Health Clinical Center of Chengdu in China.
Acute Hepatitis B Infection in a Patient With Confirmed Immunity on Long-Acting Cabotegravir/Rilpivirine.
ACG Case Rep J
January 2025
Internal Medicine, Marshall University Medical Center, Huntington, WV.
Long-acting injectable formulation of cabotegravir/rilpivirine (CAB/RPV) is a promising novel maintenance therapy for HIV infection. However, coinfection with active hepatitis B virus (HBV) infection is a contraindication to initiating this therapy. Despite guidelines, patients with HBV immunity can still contract acute HBV infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!